Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10231408 | Biotechnology Advances | 2015 | 24 Pages |
Abstract
This review discusses peptide-based vaccines in breast cancer, immune responses and clinical outcomes, which include studies on animal models and phase I, phase I/II, phase II and phase III clinical trials. Peptide-based vaccines are powerful neoadjuvant immunotherapies that can directly target proteins expressed in tumor cells, mainly tumor-associated antigens (TAAs). The most common breast cancer TAA epitopes are derived from MUC1, HER2/neu and CEA proteins. Peptides derived from TAAs could be successfully used to elicit CD8 and CD4 T cell-specific responses. Thus, choosing peptides that adapt to natural variations of human leukocyte antigen (HLA) genes is critical. The most attractive advantage is that the target response is more specific and less toxic than for other therapies and vaccines. Prominent studies on NeuVax - E75 (epitope for HER2/neu and GM-CSF) in breast cancer and DPX-0907 (HLA-A2-TAAs) expressed in breast cancer, ovarian and prostate cancer have shown the efficacy of peptide-based vaccines as neoadjuvant immunotherapy against cancer. Future peptide vaccine strategies, although a challenge to be applied in a broad range of breast cancers, point to the development of degenerate multi-epitope immunogens against multiple targets.
Keywords
PD1CTLA4TregsICAMMUC1CD4MDSCsCD8cd3FasRFADDMPRIL-2CD28Nox2BCGmannose 6-phosphate receptorsTumor-specific antigenHLA-ACTLTSABCRT helper lymphocytesIL-RHTLAPCsTCrnatural killerCeATLRscarcinoembryonic antigenHuman leukocyte antigentumor-associated antigensAntigen presenting cellsHLAimmunoglobulinsrecombinant interleukinHER2/neuBacille Calmette-Guérintransporter associated with antigen processingBreast cancer therapyTAAsBreast cancerDendritic cellMyeloid-derived suppressor cellsRegulatory T cellsendoplasmic reticulumTAPFasLtumor necrosis factorTNF-αMHCmajor histocompatibility complexintercellular adhesion moleculeMucin 1MACFas-associated protein with death domainmembrane attack complexB cell receptorT cell receptorHuman epidermal growth factor receptor 2Toll-like receptors
Related Topics
Physical Sciences and Engineering
Chemical Engineering
Bioengineering
Authors
LÃvia de Paula Peres, Felipe Andrés Cordero da Luz, Brunna dos Anjos Pultz, Paula Cristina BrÃgido, Rogério Agenor de Araújo, Luiz Ricardo Goulart, Marcelo José Barbosa Silva,